Metagenomi Therapeutics (MGX) Chardan's 8th Annual Genetic Medicines Conference summary

Company overview and technology platform

• Focuses on gene editing using novel enzymes discovered via metagenomics, enabling programmable nucleases for efficient, targeted genome editing with minimal off-target effects.

• Toolbox supports single base changes, small insertions, and corrections using both RNA- and DNA-mediated technologies.

• Platform designed to address a wide range of genetic diseases by matching technology to disease-specific genetic signatures.

• Lead program targets hemophilia A, aiming for a curative, one-time treatment for adults and children.

• Toolbox also supports large gene integrations for diseases like A1AT and Wilson’s.

Hemophilia A program and clinical data

• Proof-of-concept data from a 12-month non-human primate (NHP) study showed stable Factor VIII expression, prompting extension to a two-year study.

• Durability, lower AAV dose, and suitability for children differentiate the approach from existing therapies, addressing key commercial and clinical limitations.

• NHP data showed therapeutic Factor VIII levels (8–85% of normal) maintained over 12 months, with further optimizations improving potency and safety.

• IND-enabling studies for the development candidate to start late this year, with data expected early next year.

• Positive regulatory feedback from the FDA and strong enthusiasm from key opinion leaders and the hemophilia community.

Pipeline expansion and platform leverage

• Platform enables rapid adaptation to other secreted protein disorders with unmet needs and wide therapeutic indices.

• Indication selection focuses on secreted protein disorders with significant clinical need and favorable competitive landscapes.

• Platform approach reduces time and cost for new candidates by reusing established components and manufacturing processes.

• Ongoing preclinical advancement of additional programs, with updates expected in coming quarters.